CONMED (CNMD) Competitors $60.08 -0.65 (-1.07%) As of 03:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CNMD vs. STVN, GKOS, INSP, NARI, IRTC, BLCO, SLNO, TMDX, PRCT, and NVSTShould you be buying CONMED stock or one of its competitors? The main competitors of CONMED include Stevanato Group (STVN), Glaukos (GKOS), Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), PROCEPT BioRobotics (PRCT), and Envista (NVST). These companies are all part of the "medical equipment" industry. CONMED vs. Stevanato Group Glaukos Inspire Medical Systems Inari Medical iRhythm Technologies Bausch + Lomb Soleno Therapeutics TransMedics Group PROCEPT BioRobotics Envista CONMED (NYSE:CNMD) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Does the MarketBeat Community believe in CNMD or STVN? CONMED received 6 more outperform votes than Stevanato Group when rated by MarketBeat users. However, 63.27% of users gave Stevanato Group an outperform vote while only 45.68% of users gave CONMED an outperform vote. CompanyUnderperformOutperformCONMEDOutperform Votes3745.68% Underperform Votes4454.32% Stevanato GroupOutperform Votes3163.27% Underperform Votes1836.73% Does the media prefer CNMD or STVN? In the previous week, Stevanato Group had 7 more articles in the media than CONMED. MarketBeat recorded 18 mentions for Stevanato Group and 11 mentions for CONMED. CONMED's average media sentiment score of 0.97 beat Stevanato Group's score of 0.91 indicating that CONMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CONMED 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 7 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CNMD or STVN? CONMED presently has a consensus target price of $62.20, indicating a potential upside of 3.48%. Given CONMED's higher possible upside, equities research analysts plainly believe CONMED is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CONMED 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more volatility and risk, CNMD or STVN? CONMED has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Is CNMD or STVN a better dividend stock? CONMED pays an annual dividend of $0.80 per share and has a dividend yield of 1.3%. Stevanato Group pays an annual dividend of €0.06 per share and has a dividend yield of 0.2%. CONMED pays out 21.1% of its earnings in the form of a dividend. Stevanato Group pays out 11.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stevanato Group has raised its dividend for 1 consecutive years. Is CNMD or STVN more profitable? Stevanato Group has a net margin of 10.47% compared to CONMED's net margin of 10.13%. CONMED's return on equity of 14.31% beat Stevanato Group's return on equity.Company Net Margins Return on Equity Return on Assets CONMED10.13% 14.31% 5.64% Stevanato Group 10.47%9.86%5.79% Which has higher valuation and earnings, CNMD or STVN? Stevanato Group has lower revenue, but higher earnings than CONMED. CONMED is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCONMED$1.32B1.41$132.42M$3.8015.82Stevanato Group$1.10B6.62$157.62M$0.5147.29 SummaryStevanato Group beats CONMED on 12 of the 20 factors compared between the two stocks. Get CONMED News Delivered to You Automatically Sign up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNMD vs. The Competition Export to ExcelMetricCONMEDElectromedical equipment IndustryMedical SectorNYSE ExchangeMarket Cap$1.86B$3.26B$5.36B$19.50BDividend Yield1.43%1.76%5.44%3.95%P/E Ratio14.1816.9825.5834.73Price / Sales1.4167.70404.2935.20Price / Cash9.1344.0938.3117.51Price / Book1.933.586.744.73Net Income$132.42M$87.85M$3.23B$1.02B7 Day Performance7.39%3.08%2.20%4.65%1 Month Performance16.26%16.23%9.98%11.31%1 Year Performance-17.42%-16.99%15.18%6.39% CONMED Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNMDCONMED4.1674 of 5 stars$60.08-1.1%$62.20+3.5%-14.6%$1.86B$1.32B14.174,100STVNStevanato Group1.0189 of 5 stars€22.11+3.4%N/A+8.3%$6.70B$1.10B47.044,650Analyst RevisionNews CoverageGap DownGKOSGlaukos4.6925 of 5 stars$86.80-0.9%$137.62+58.5%-14.4%$4.96B$383.48M-30.24780Positive NewsINSPInspire Medical Systems4.7475 of 5 stars$159.67-0.1%$218.90+37.1%-6.7%$4.75B$802.80M92.29760Positive NewsNARIInari MedicalN/A$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800IRTCiRhythm Technologies1.2442 of 5 stars$135.76+3.5%$128.55-5.3%+39.2%$4.33B$591.84M-37.301,790Positive NewsHigh Trading VolumeBLCOBausch + Lomb4.3076 of 5 stars$11.37-1.1%$16.14+41.9%-22.7%$4.02B$4.83B-12.4912,500News CoverageHigh Trading VolumeSLNOSoleno Therapeutics4.6136 of 5 stars$76.49+1.7%$104.67+36.8%+70.5%$3.82BN/A-23.0430Earnings ReportAnalyst RevisionPositive NewsTMDXTransMedics Group1.863 of 5 stars$92.21+2.5%$124.20+34.7%-8.7%$3.12B$441.54M98.10210Earnings ReportPositive NewsPRCTPROCEPT BioRobotics2.7798 of 5 stars$54.41-2.2%$90.00+65.4%-13.1%$3.01B$249.12M-27.90430NVSTEnvista3.4974 of 5 stars$17.00+0.1%$20.38+19.9%+0.1%$2.88B$2.50B-2.6212,700 Related Companies and Tools Related Companies STVN Competitors GKOS Competitors INSP Competitors NARI Competitors IRTC Competitors BLCO Competitors SLNO Competitors TMDX Competitors PRCT Competitors NVST Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CNMD) was last updated on 5/13/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWarning: Massive IPO Predicted for May 14?The #1 venture capitalist in America predicts that the biggest IPO in history will take place on Wednesday, Ma...Paradigm Press | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CONMED Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CONMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.